Reply To: Ricolinostat is Not a Highly Selective HDAC6 Inhibitor

Overview

Journal Nat Cancer

Specialty Oncology

Date 2023 Jun 15

PMID 37322366

Authors

Jose Silva

Jiyang Yu

Kevin Kalinsky

Affiliations

Soon will be listed here.

Citing Articles

Phase separation rewires chromatin in breast cancer.

Benedetti R, Altucci L Nat Cancer. 2024; 5(11):1602-1604.

PMID: 39455848 DOI: 10.1038/s43018-024-00843-9.

References

Visvader J, Lindeman G . Mammary stem cells and mammopoiesis. Cancer Res. 2006; 66(20):9798-801. DOI: 10.1158/0008-5472.CAN-06-2254. View

Depetter Y, Geurs S, De Vreese R, Goethals S, Vandoorn E, Laevens A . Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. Int J Cancer. 2019; 145(3):735-747. DOI: 10.1002/ijc.32169. View

Winkler R, Magdefrau A, Piskor E, Kleemann M, Beyer M, Linke K . Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition. Oncogene. 2022; 41(40):4560-4572. PMC: 9525236. DOI: 10.1038/s41388-022-02450-3. View

Teng X, Dayhoff-Brannigan M, Cheng W, Gilbert C, Sing C, Diny N . Genome-wide consequences of deleting any single gene. Mol Cell. 2013; 52(4):485-94. PMC: 3975072. DOI: 10.1016/j.molcel.2013.09.026. View

Zeleke T, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H . Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nat Cancer. 2022; 4(2):257-275. PMC: 9992270. DOI: 10.1038/s43018-022-00489-5. View

Sharif T, Martell E, Dai C, Ghassemi-Rad M, Hanes M, Murphy P . HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells. Autophagy. 2018; 15(4):686-706. PMC: 6526821. DOI: 10.1080/15548627.2018.1548547. View

Hao L, He Q, Wang Z, Craven M, Newton M, Ahlquist P . Limited agreement of independent RNAi screens for virus-required host genes owes more to false-negative than false-positive factors. PLoS Comput Biol. 2013; 9(9):e1003235. PMC: 3777922. DOI: 10.1371/journal.pcbi.1003235. View

Namdar M, Perez G, Ngo L, Marks P . Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A. 2010; 107(46):20003-8. PMC: 2993347. DOI: 10.1073/pnas.1013754107. View

Bai J, Lei Y, An G, He L . Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathway. PLoS One. 2015; 10(3):e0121247. PMC: 4361412. DOI: 10.1371/journal.pone.0121247. View

10.

Lechner S, Malgapo M, Gratz C, Steimbach R, Baron A, Ruther P . Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022; 18(8):812-820. PMC: 9339481. DOI: 10.1038/s41589-022-01015-5. View

11.

Santo L, Hideshima T, Kung A, Tseng J, Tamang D, Yang M . Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012; 119(11):2579-89. PMC: 3337713. DOI: 10.1182/blood-2011-10-387365. View

12.

Lee E, Tan-Wasielewski Z, Matulonis U, Birrer M, Wright A, Horowitz N . Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019; 29:118-122. PMC: 6712364. DOI: 10.1016/j.gore.2019.07.010. View

13.

Vogl D, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R . Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2017; 23(13):3307-3315. PMC: 5496796. DOI: 10.1158/1078-0432.CCR-16-2526. View

14.

Amengual J, Lue J, Ma H, Lichtenstein R, Shah B, Cremers S . First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma. Oncologist. 2021; 26(3):184-e366. PMC: 7930426. DOI: 10.1002/onco.13673. View

15.

Zhang J, Ma J, Trinh R, Heijnen C, Kavelaars A . An HDAC6 inhibitor reverses chemotherapy-induced mechanical hypersensitivity via an IL-10 and macrophage dependent pathway. Brain Behav Immun. 2021; 100:287-296. PMC: 8766942. DOI: 10.1016/j.bbi.2021.12.005. View